Lung cancer clue hunt: why do only 40% respond to immunotherapy?
NCT ID NCT07608835
First seen May 29, 2026 · Last updated Jun 15, 2026 · Updated 4 times
Summary
This study aims to find biological markers (biomarkers) in the blood and tumors of people with non-small cell lung cancer that can predict whether immunotherapy will work. Researchers will compare these markers between people whose cancer responds and those whose does not. The goal is to improve treatment selection and discover new targets for therapy. About 200 adults with suspected or confirmed lung cancer will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rochigneux
RECRUITINGMarseille, Institut Paoli Calmettes, 13009, France
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.